The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved weekly disease severity regardless of prior anti-IgE biologic use, ...
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Septerna, Inc. yesterday and set a price target of $25.00. The company’s shares closed yesterday at $23.77. Claim 60% off TipRanks ...
The average one-year price target for Septerna (NasdaqGM:SEPN) has been revised to $28.22 / share. This is an increase of 20.29% from the prior estimate of $23.46 dated November 7, 2025. The price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback